知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

300 条记录 (耗时 0.051 秒)

    ASRGL1 IN ENDOMETRIAL CANCER
    138.
    发明申请
    ASRGL1 IN ENDOMETRIAL CANCER 审中-公开
    ASRGL1在子宫内膜癌

    公开(公告)号：US20160054324A1

    公开(公告)日：2016-02-25

    申请号：US14782538

    申请日：2014-04-04

    申请人： ATLAS ANTIBODIES AB

    发明人： Per-Henrik Edqvist ,  Fredrik Ponten

    IPC分类号： G01N33/574 ,  C07K16/40

    CPC分类号： G01N33/57442 ,  C07K16/40 ,  C07K2317/34 ,  G01N2333/982 ,  G01N2800/52 ,  G01N2800/54

    摘要： There is provided a method for determining whether a mammalian subject having an endometrial cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of ASRGL1 in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to the second group.

    摘要翻译： 提供了一种用于确定具有子宫内膜癌的哺乳动物受试者是否属于第一组或第二组的方法，其中第一组受试者的预后优于第二组受试者的预后，包括以下步骤： a）评估早先从受试者获得的样本的至少一部分中的ASRGL1的量，并确定对应于评估量的样本值; b）将所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则c1）认定所述对象属于所述第一组; 并且如果所述样本值小于或等于所述参考值，则c2）认定所述对象属于所述第二组。

    Methods of determining efficacy of treatment in a subject having heart failure
    140.
    发明授权
    Methods of determining efficacy of treatment in a subject having heart failure 有权
    确定患有心力衰竭的受试者的治疗功效的方法

    公开(公告)号：US09239333B2

    公开(公告)日：2016-01-19

    申请号：US14267487

    申请日：2014-05-01

    申请人： Critical Care Diagnostics, Inc.

    发明人： James V. Snider

    IPC分类号： G01N33/53 ,  G01N33/68 ,  C07K14/47 ,  C07K14/715

    CPC分类号： G01N33/6893 ,  C07K14/47 ,  C07K14/4726 ,  C07K14/715 ,  G01N33/53 ,  G01N33/68 ,  G01N33/6869 ,  G01N2333/4724 ,  G01N2333/7155 ,  G01N2800/32 ,  G01N2800/325 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/56

    摘要： Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 in a biological sample from the subject and determining a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the kit to evaluate the risk of an adverse clinical outcome in a subject, to decide whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis) or to initiate or terminate treatment, to select a subject for participation in a clinical study, and/or to select treatment for a subject.

    摘要翻译： 提供了评估受试者的不良临床结果的风险的方法，决定是否释放或继续治疗受试者（例如，以住院患者为对象），或开始或终止治疗，选择参与临床的受试者 研究和选择对受试者的治疗性治疗，其包括确定来自受试者的生物样品中的ST2水平，并确定来自受试者的生物样品中的半乳凝素-3的水平。 还提供了包含特异性结合ST2的抗体，特异性结合半乳聚糖-3的抗体的试剂盒，以及使用该试剂盒评估受试者的不良临床结果风险的指示，以决定是否释放或继续 治疗受试者（例如住院治疗）或开始或终止治疗，选择参与临床研究的受试者和/或选择对象的治疗。